Understanding how these genes regulate SMC-to-MAC transitions may reveal new mechanisms of SMC plasticity and vascular inflammation, highlighting FHOD1 and IRF7 as potential therapeutic targets to mitigate vascular remodeling and atherosclerosis progression. This evidence concerns the gene FHOD1 and atherosclerosis.